St. Jude Care & Treatment

Menu

Close

Closed

HPTN 083-01 HIV Prevention Study

About this study

PrEP is medicine given to prevent Human Immunodeficiency Virus (HIV) infection before it occurs. Cabotegravir is a new drug that has been found to be effective at preventing HIV among adults.

HPTN 083-01 was a study to find out if long-acting, injectable cabotegravir (CAB LA) for PrEP (pre-exposure prophylaxis) is safe and acceptable to use in adolescents.

St. Jude was one of four sites participating in the study. Denver, Chicago and Boston were the other study sites. The study enrolled a total of 50 participants at all locations.

Who was eligible for the HPTN 083-01 study?

Participants were eligible for this study if:

  • They were 17 years old or younger
  • They did not have HIV
  • They were assigned male at birth
  • They had or were interested in sexual experiences with male or transgender partners

Why was the study important?

More than 20% of new HIV infections occur among young people ages 13 to 24. PrEP medicine is an effective way to prevent HIV infection in at-risk adolescents and adults.

Only two PrEP medicines are currently approved by the U.S. Food and Drug Administration. Both of these medicines are taken as pills. A long-acting, injectable form of PrEP, such as cabotegravir, could give at-risk individuals another preventive option.

Request a referral

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.

Overview

Full title:

HPTN 083-01

Study goal:

To find out if long-acting, injectable cabotegravir (CAB LA) for PrEP (pre-exposure prophylaxis) is safe and acceptable to use in adolescents

Diagnosis:

HIV

Age:

17 years or younger

Clinical trials categories:

Human Immunodeficiency Virus (HIV) Infection Infectious Diseases

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.

 

Learn more